Wednesday, June 10, 2026

Intelligence Β· Clinical Development

Pipeline search results

Programs matching β€œrecombinant” across our ClinicalTrials.gov index β€” phase, modality, sponsor, and trial IDs.

Matching programs 118
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 118 pipeline programs matching "recombinant" from NovaPharmaNews Clinical Development Intelligence β€” phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

118 results for β€œrecombinant” Back to intelligence hub

Search results

Page 2 of 5
  1. Recombinant human tissue kallikrein

    DiaMedica Therapeutics

    Acute Stroke

    phase 3 small molecule active

    1 trial
  2. Recombinant von Willebrand factor (rVWF)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    2 trials
  3. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial
  4. recombinant human thrombopoietin

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial
  5. recombinant human thrombopoietin (rhTPO); dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial
  6. recombinant human thrombopoietin (rhTPO); rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule terminated

    1 trial
  7. recombinant interferon alfa

    United Therapeutics Europe Ltd

    Melanoma (Skin)

    phase 3 mab completed

    1 trial
  8. rhIDU (recombinant human-Alpha-L-Iduronidase)

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    phase 3 mab completed

    1 trial
  9. rituximab; recombinant human thrombopoietin (rhTPO)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial
  10. von Willebrand factor (Recombinant)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    1 trial
  11. Aerosolized, Recombinant Alpha 1-Antitrypsin

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 2 small molecule completed

    2 trials
  12. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial
  13. CTP-VLP-002

    CanSino Biologics

    Poliomyelitis

    phase 2 mab active

    1 trial
  14. JSVCT099

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab completed

    1 trial
  15. KLWS-V502-02

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial
  16. Multivalent recombinant OspA Lyme Borreliosis Vaccine

    Takeda

    Prophylaxis of Lyme Borreliosis

    phase 2 mab completed

    1 trial
  17. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial
  18. Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Psoriasis

    phase 2 small molecule active

    1 trial
  19. Recombinant Anti-IL-1Ξ² Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial
  20. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial
  21. Recombinant COVID-19 Vaccine (CHO cell,NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial
  22. Recombinant COVID-19 Vaccine (CHO cell,NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial
  23. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  24. Recombinant Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure With Hemodialysis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs β€” not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars β€” improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes β€” use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.